Clinical Trial Detail

NCT ID NCT04301778
Title Durvalumab in Combination With a CSF-1R Inhibitor (SNDX-6532) Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma
Recruitment Not yet recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

intrahepatic cholangiocarcinoma


Durvalumab + SNDX-6352

Age Groups: senior adult

No variant requirements are available.